Pharma
Regulatory
Karyopharm’s Xpovio (selinexor) Receives FDA’s Accelerated Approval for Relapsed/Refractory Multiple
Shots: The accelerated approval is based P-IIb STORM study results assessing Xpovio (80mg) + dexamethasone (20mg) in 122 patients with RRMM, prior treated with 4 therapies with the refractory disease […]readmore